Pharmaceutical Pricing and Medical Innovation
Featured Topics
Lead story
Other featured articles
-
It’s Hard to Lower Drug Prices, If You Don’t Know What They Are
In an op-ed for The Hill, Professor Neeraj Sood writes that until legislators and regulators understand where the profits are flowing in the prescription drug distribution system, bills to control prices risk being ineffective.
-
CBO Estimate on Pelosi Drug Bill Misses its Long-Term Impact on Health
The CBO estimated that the Pelosi drug pricing reform legislation proposed would save Medicare $345 billion over seven years. It failed to look at the long-term effect on new drug discovery and the impact on population health.
-
Accounting for Hope: Using ‘Mean Survival Gain’ to Price New Cancer Drugs
Outrage about the rising prices of prescription drugs has put cancer drugs in the spotlight. But there’s an important question that needs to be asked: What is the best metric to evaluate them?
-
Expanding the Role of the Patient-Centered Outcomes Research Institute: Reauthorization and Facilitating Value Assessments
Should Congress reauthorize funding for the Patient-Centered Outcomes Research Institute (PCORI)? Professor William Padula writes the PCORI can generate research relevant for shifting to value-based healthcare.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Pharmaceutical Pricing and Medical Innovation
Our Work In Pharmaceutical Pricing and Medical Innovation
-
Understanding the Bipartisan Senate Finance Prescription Drug Reform Package
“USC-Brookings Schaeffer Initiative experts unpack the bipartisan Senate Finance prescription drug reform package.
-
Who Would Have Believed it? Markets Can Reduce the ‘True’ Price of Cancer Drugs
When it comes to cancer, however, it is the price of health — not the price of drugs — that matters. As we think about ways to wring value out of the health care system, we acknowledge that CMS reforms and markets seem to be working in therapeutic areas with rapid innovation.
Categorized in -
State Drug Pricing Transparency Laws: Numerous Efforts, Most Fall Short
166 recently enacted prescription drug pricing laws were analyzed to identify those that contained price transparency measures. Of these, 35 bills in 22 states include a transparency component, but only 7 were deemed to be informative.
Categorized in -
Data Visualization: State Drug Transparency Laws
States are increasingly enacting price transparency laws designed to provide regulators or the public with more information about how entities in the drug distribution system set prices. The data visualization summarizes the 35 drug pricing transparency bills enacted in states between 2015 and 2018.
Categorized in -
Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017
High and rising launch prices of new cancer drugs have raised American public stakeholder and policy concern. A key policy question is whether the clinical gains offered by these drugs in treating specific cancer indications justify the price increases.
Categorized in -
Considerations For Expanding International Reference Pricing Beyond Medicare Part B
Experts lay out considerations for expanding the administration’s proposed model beyond Medicare Part B drugs.